Monashee Investment Management LLC Invests $2.34 Million in uniQure N.V. $QURE

Monashee Investment Management LLC purchased a new position in shares of uniQure N.V. (NASDAQ:QURE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 40,000 shares of the biotechnology company’s stock, valued at approximately $2,335,000. Monashee Investment Management LLC owned approximately 0.07% of uniQure at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Aberdeen Group plc lifted its holdings in uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after purchasing an additional 189,029 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of uniQure in the 2nd quarter valued at $29,217,000. JPMorgan Chase & Co. boosted its holdings in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after buying an additional 1,491,486 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in uniQure by 185.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after acquiring an additional 1,012,585 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of uniQure by 15.7% during the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Unusual bullish options flow — heavy call buying (24,345 calls, ~181% above typical volume) suggests some traders are speculating on a near‑term rebound or event‑driven move.
• Negative Sentiment: Fresh FDA controversy: coverage highlights critical comments from FDA leadership about uniQure’s rejected rare‑disease therapy, which markets see as increasing regulatory risk for the program. uniQure: Shares Tumble On Fresh FDA Controversy – What Investors Should Know
• Negative Sentiment: FDA commissioner comments drew broad media coverage and were cited as the main driver of the selloff, amplifying short‑term downside as investors reassess approval odds. UniQure plummets as FDA’s Marty Makary disparages rejected rare disease drug
• Negative Sentiment: Multiple securities‑class action filings and firm notices: several law firms are publicizing suits or seeking lead plaintiffs for alleged misstatements during a specified class period — increasing legal and reputational risk and likely weighing on sentiment. Representative notices: DJS Law Group. uniQure N.V. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – QURE
• Negative Sentiment: Broad wave of law‑firm alerts and reminder notices (Rosen, Pomerantz, Faruqi, Robbins, Berger Montague, etc.) highlights that litigation momentum is building and that April 13, 2026 lead‑plaintiff deadlines are approaching — an added near‑term overhang. Example: Rosen Law Firm reminder. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – QURE
• Negative Sentiment: Market reaction summaries: analyst/news pieces attribute a large intraday drop to the FDA remarks and resulting uncertainty, reinforcing negative sentiment. Why Is uniQure Stock Down 30% Today?

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Chardan Capital reiterated a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th. Wolfe Research started coverage on uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Leerink Partners cut their price objective on uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a report on Monday, November 10th. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, Barclays assumed coverage on uniQure in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 target price for the company. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $58.33.

uniQure Trading Down 8.6%

Shares of QURE stock opened at $15.63 on Friday. The stock has a market cap of $973.59 million, a P/E ratio of -3.56 and a beta of 0.66. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock has a 50 day simple moving average of $23.46 and a 200 day simple moving average of $29.70.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 6,217 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $148,337.62. Following the completion of the transaction, the chief financial officer owned 211,513 shares of the company’s stock, valued at $5,046,700.18. The trade was a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthew C. Kapusta sold 12,378 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $295,339.08. Following the completion of the transaction, the chief executive officer owned 639,076 shares of the company’s stock, valued at $15,248,353.36. The trade was a 1.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 50,598 shares of company stock worth $1,248,588 over the last three months. Company insiders own 4.79% of the company’s stock.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.